蛛网膜下隙注射吗啡术后镇痛

目的　探讨蛛网膜下隙注射吗啡术后镇痛的临床效果及不良反应。方法　ASAⅠ～Ⅱ级 6 0例择期妇科手术病人 ,随机分为两组 ,每组 30例 ,均采用腰麻 硬膜外联合阻滞。腰麻用药为0 5 %重比重布比卡因 10mg ,然后硬膜外腔置管。研究组于腰麻药中加入吗啡 0 2 5mg ,对照组则于硬膜外腔注射吗啡 2mg。术后行视觉模拟评分 (VAS)、Ramsay镇静评分、BCS(Bruggrmanncomfortscale)舒适评分并观察不良反应发生情况。结果　蛛网膜下隙吗啡组术后完全无痛时间和持续镇痛时间明显长于硬膜外吗啡组 ,VAS评分明显低于硬膜外吗啡组 (P <0 0 5或P <0 0 1)。Ramsay评分和BCS评分明显高于硬膜外吗啡组 (P <0 0 5或P <0 0 1)。蛛网膜下隙吗啡组术后不良反应发生率明显增加 (P <0 0 5 )。结论　蛛网膜下隙注射吗啡镇痛效果确切、持续时间长 ,但不良反应发生率较高于硬膜外吗啡镇痛     

Intrathecal morphine for postpartum tubal ligation postoperative analgesia

Intrathecal morphine (ITM) provides effective postoperative cesarean delivery analgesia but has not been reported for postoperative postpartum tubal ligation (PPTL) analgesia. We designed this prospective, randomized, double-blinded study to determine the efficacy of 100 microg ITM for postoperative PPTL analgesia. Sixty-six women received spinal anesthesia with 60 mg (1.2 mL) of 5% hyperbaric lidocaine, 10 microg (0.2 mL) of fentanyl, and either 0.2 mL of 0.9% saline (normal saline; NS) or 100 microg (0.2 mL) of morphine (morphine sulfate, MS). Postoperative analgesia was limited to patient-controlled IV analgesia morphine. Six women (three NS and three MS) were excluded because of major protocol violations. Twenty-four-hour patient-controlled IV analgesia morphine use was (mean +/- SD) 39.6 +/- 19.6 mg in the NS group and 1.1 +/- 2.5 mg in the MS group (P < 0.0000001). Visual analog scale scores for crampy and incisional pain (rest and movement) were significantly higher in the NS group compared with the MS group at 4, 8, 12, and 24 h (P < 0.001). The adverse effect profile was similar between groups. Visual analog scale satisfaction scores (mean +/- SD) were 96.6 +/- 16.0 in the MS group and 84.2 +/- 23.6 in NS group (P < 0.05). The results of this study indicate that women experience significant postoperative pain after PPTL surgery, and this pain is effectively obviated by 100 microg ITM. IMPLICATIONS: This investigation documents the extent of the significant postoperative pain experienced by women after routine postpartum tubal ligation surgery and demonstrates the efficacy of a small dose (100 microg) of intrathecal morphine to obviate this pain with minimal adverse effects.     

Intrathecal morphine for analgesia after postpartum bilateral tubal ligation

Postpartum bilateral tubal ligation (PPBTL) causes postoperative pain. We designed this study to determine the efficacy of 50 microg intrathecal morphine for analgesia after PPBTL. Sixty-five women received spinal anesthesia with 12.75 mg hyperbaric bupivacaine, 20 microg of fentanyl, and either 50 microg of morphine (morphine group) or 0.05 mL of saline (control group). Postoperative analgesia was provided with regular naproxen 500 mg and oxycodone 5 mg/acetaminophen 325 mg mixture as needed. Overall, satisfaction was higher (P=0.003) and pain was less intense at rest (P=0.008) and on movement (P <0.0001) in the morphine group. There was no significant overall difference in nausea, pruritus, or sedation scores, but vomiting occurred more frequently in the morphine group (21.4% versus 3.5%; P=0.052). In post hoc comparisons, pain at rest within the morphine group was significantly less at 4 h (P=0.006), pain on movement was significantly less at 4 h (P=0.002) and 12 h (P=0.0004), and pruritus was significantly more frequent at 12 h (P=0.002) compared with the control group. Oxycodone 5 mg/acetaminophen 325 mg mixture consumption was significantly smaller (P=0.006) and the time to first request of analgesia was significantly longer (P=0.006) in the morphine group. We conclude that the addition of 50 microg of morphine to intrathecal hyperbaric bupivacaine and fentanyl provides improved postoperative analgesia in women undergoing PPBTL.     

Intrathecal morphine reduces breakthrough pain during labour epidural analgesia

BACKGROUND: When using the combined spinal-epidural (CSE) technique forlabour analgesia, parturients often experience breakthroughpain after the spinal medication has receded. We tested thehypothesis that a small dose of intrathecal morphine would reducebreakthrough pain. METHODS: This was a randomized, double-blind, placebo-controlled trial.Subjects were randomized to receive either 100 µgof morphine (MS) or placebo (PLCB) with the spinal injectionof bupivacaine and fentanyl. Assessments included need for supplementationduring labour analgesia, use of pain medications for 24 hafter delivery, and side-effects. The primary end-point wasthe rate of breakthrough pain. RESULTS: Sixty subjects were enrolled, 55 subjects completed the trial.The MS group had a significantly lower rate of breakthroughpain than the PLCB group [0.6 (0.6) vs 1.1 (0.8) episodes perpatient; P < 0.01], and longer time to first episode of breakthroughpain (300 vs 180 min; P = 0.03). The MS group used 75%less opioid medications during the subsequent 24 h, buthad a 17% incidence of nausea. CONCLUSIONS: The addition of small dose of morphine to the spinal componentof the CSE technique improved the effectiveness of epidurallabour analgesia and reduced the need for pain medications over24 h, but resulted in a small increase in nausea.     

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain

Purpose

Ketamine has been administered epidurally and intrathecally for operative and post-operative pain control. Animal studies showed potentiation of analgesia induced by ketamine and morphine. We hypothesized that intrathecal ketamine would potentiate the effects of intrathecal morphine in the treatment of cancer pain.

Methods

A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients. A two-phase protocol was used; phase M, intrathecal morphine alone twice daily; phase M+K, co-administration of ketamine (1.0 mg) with morphine intrathecally twice daily. The dose of morphine was titrated upwards until acceptable pain relief was achieved, defined by numeric rating scales (0–10) ≤ 3, and the rescue dose of morphine was less than 5 mg after each intrathecal administration for two days. The dose of intrathecal morphine was defined as the effective dose.

Results

The effective dose of intrathecal morphine in phase M of 0.38 ± 0.04 mg · day^?1 was higher than that in phase M+K (0.17 ± 0.02 mg · day^?1) (P < 0.05). The average pain scales were 7.95 ± 0.25 before intrathecal drug administration. Pain scales were decreased to 2.2 ± 0.17 (P < 0.05) in phase M and 1.95 ± 0.20 (P < 0.05) in phase M+K after the effective dose of morphine had been reached. No serious side effects were observed in this study.

Conclusion

The present study demonstrates that ketamine enhances the analgesic effect of morphine, thus reducing the dose of intrathecal morphine.     

Intrathecal and intraventricular morphine for pain in cancer patients: initial study

Intractable pain in six cancer patients was treated with lumbar intrathecal morphine (two patients) and intraventricular morphine (four patients). Daily percutaneous injections of morphine through Ommaya reservoirs were made. Initially, 1 mg of lumbar intrathecal morphine resulted in pain relief for 10 to 14 hours, and 2.5 to 4.0 mg of intraventricular morphine gave relief for 12 to 24 hours. This treatment was continued for 3 to 7 months in three of the adults. Morphine requirements gradually increased. Side effects were minimal, and there were no complications.     

Intrathecal morphine provides effective and safe analgesia in children after cardiac surgery

BACKGROUND: The purpose of this prospective, randomized, blinded to observer study was to assess the analgesic effect and safety of intrathecal morphine (ITM) in post-operative pain control in children after heart surgery with a sternotomy incision. METHODS: Eighty children, 3-55 kg in body weight, undergoing elective cardiac surgery with opioid-based anaesthesia were randomly divided into two treatment groups to receive either 20 micrograms/kg ITM at induction of anaesthesia or control. To standardize the protocol for administration of post-operative rescue intravenous morphine boluses and infusion (20-60 micrograms/kg/h), the Cardiac Analgesic Assessment Scale (CAAS) was used. RESULTS: Nine patients were excluded from the study after randomization. Thirty-five patients were enrolled to the ITM group and 36 to the control group. The groups were similar for demographics and intra-operative clinical characteristics. The mean time for the first intravenous morphine dose from ITM administration or equivalent time zero in the control group was significantly longer (P = 0.003) in the ITM group compared with the control group (12.3 vs. 8.7 h). Time from Paediatric Intensive Care Unit (PICU) admission to the start of intravenous morphine was also significantly longer (P = 0.01) in the ITM group (6.0 vs. 3.4 h). The total intravenous morphine consumption over the mean 19 post-operative hours was significantly lower (P = 0.03) in the ITM group. However, the use of ITM did not result in earlier extubation or earlier discharge from the PICU. Of the 35 patients who received ITM at induction of anesthesia, 20% (n = 7) did not require any additional morphine in the PICU compared with three out of 36 control group patients. This did not reach statistical significance. The incidence of adverse events was low in both groups. CONCLUSIONS: An ITM dose of 20 micrograms/kg had a significant (P = 0.03) intravenous morphine-sparing effect after cardiac surgery. Effective analgesia was observed for 12 h after administration of intrathecal morphine.     

Intrathecal morphine for postoperative analgesia in children after selective dorsal root rhizotomy

The authors report their experience with low doses (0.007-0.015 mg/kg), moderate doses (0.016-0.025 mg/kg), and high doses (0.026-0.035 mg/kg) of intrathecal morphine for postoperative analgesia after selective dorsal root rhizotomy surgery in 50 children, aged 3 to 12 years. After closure of the dura, a single dose of preservative-free morphine was injected into the subarachnoid space, and patients were assessed for 48 hours for level of comfort and side effects. The three doses of morphine provided equivalent analgesia and similar side effects. The duration of postoperative analgesia ranged from 3 to 48 hours (mean, 12.2 +/- 9.5 h). Common side effects were limited to nausea and vomiting (42%) and mild facial pruritus. No patient experienced late respiratory depression or generalized pruritus. The authors conclude that low doses of intrathecal morphine is as effective as moderate or high doses of morphine for reducing pain in the immediate postoperative period. Intrathecal morphine provides excellent analgesia after selective dorsal rhizotomy.     

Intrathecal morphine. Double-blind evaluation of optimal dosage for analgesia after major lumbar spinal surgery.

STUDY DESIGN: A prospective, randomized, double-blind study. OBJECTIVES: To evaluate the efficacy and safety of three different dosages of intrathecal morphine sulfate for postoperative analgesia after lumbar spinal fusion. SUMMARY OF BACKGROUND DATA: Analgesia and respiratory depression after intrathecal morphine sulfate injection are dose related. The optimal dose to use for major spinal surgery is not known. METHODS: Sixty patients undergoing posterolateral lumbar fusion with or without decompression were divided randomly into 3 groups of 20 patients each. Anesthesia, monitoring, and surgery were similar for all patients. Just before closing of the wound, morphine sulfate was injected into the dural sack under direct visualization. Patients in groups 1-3 received 0.2 mg, 0.3 mg, and 0.4 mg morphine, respectively. Routine analgesia, consisting of diclofenac, was prescribed to use if necessary. Measurements were made and compared between the groups at zero hours (on admission to the Intensive Care Unit), 6 hours, 12 hours, 18 hours, and 24 hours after surgery. RESULTS: At zero hours and at 12 hours after surgery, pain levels were similar in groups 2 and 3, but were significantly higher in group 1 (P < 0.05). The respiratory rate was significantly lower in group 3 than in the other two groups (P < 0.05), and the arterial CO2 tension (PaCO2) was consistently higher in group 3. PaCO2 decreased in all three groups over the first 24 hours. Pruritus and nausea did not differ among the three groups. CONCLUSIONS: For adult patients undergoing posterolateral lumbar fusion, 0.3 mg (0.004 mg/kg) is probably the optimal dose of intrathecal morphine to manage pain.     

Intrathecal morphine for off-pump coronary artery bypass patients

Due to the fact that patients have increased mental alertness following off-pump coronary artery bypass (OPCAB), pain management in the immediate postoperative period is a major concern. Thirty-two patients underwent OPCAB grafting, 20 received 5 mcg/kg morphine sulfate intrathecally. This group was compared with 12 patients who did not receive intrathecal morphine. All patients were verbally evaluated for pain using the Wong-Baker Visual Analog Scale at eight, 12 and 24 hours. All the scores were highly statistically significant in favor of the intrathecal group. No significant complications were seen in this group of patients. It is concluded that intrathecal morphine at 5 mcg/kg is effective and safe in maintaining comfort for OPCAB patients in the immediate postoperative period.     

Intrathecal analgesia. Apropos of 50 cases

Fifty patients with intractable pain, mainly of neoplastic origin, were treated by morphine through unidose drug delivery system. Criteria of selection of the patients and technical procedures are reported. Most common side effects are nausea and dysuria but can be effectively prevented. The most severe complications are leakage of cerebro spinal fluid with or without meningitis. The success rate at 20 days is 80% as well in pelvic pain as in subdiaphragmatic extra cephalic pain.     

Intrathecal morphine in cardiac surgery

The effects of intrathecal morphine in 60 patients undergoing open-heart surgery were studied in an observer-blind control trial. The patients were randomly allocated into three groups of 20 each: (A) Control, (B) 2 mg and (C) 4 mg of intrathecal morphine. This study confirms that intrathecal morphine provides useful post-operative analgesia. Patients given intrathecal morphine required less postoperative analgesia and sedation and their respiratory function tests were less depressed than the control group. Since the completion of this study, reports have suggested that 1 mg of morphine intrathecally avoids the serious complications of respiratory depression. In the study described, the patients were electively ventilated post-operatively and respiratory depression was therefore not a problem. Of the other associated side-effects of intrathecal morphine, vomiting (20%) and pruritus (20%) proved the most troublesome.     

Intrathecal morphine for postoperative analgesia in an infant with bronchopulmonary dysplasia following upper abdominal surgery

We present a case of severe bronchopulmonary dysplasia in which intrathecal morphine was successfully used for analgesia after a Nissen fundoplication and gastrostomy. Various options for anaesthesia are discussed with the knowledge that two previous procedures had been complicated by congestive cardiac failure and increased respiratory failure.     

Intrathecal diamorphine compared with morphine for postoperative analgesia after caesarean section under spinal anaesthesia

A randomized, double-blind study of 40 women was performed to compare patient controlled anaesthesia (PCA) morphine requirements after spinal anaesthesia for elective Caesarean section. The women received 0.2 mg of either morphine or diamorphine mixed with 0.5% bupivacaine in 8% dextrose. There were no significant differences between the groups in terms of VAS for pain, either while supine or trying to turn over. The median VAS for itching were significantly higher in the morphine group at 3, 4, 6, 8 and 12 h. Similarly, the VAS for drowsiness were significantly higher in the morphine group at 6 and 8 h. Overall there was no difference in the 24-h PCA morphine demands between the two groups (diamorphine patients 5.5 mg, morphine patients 5.0 mg.